Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Autolus Therapeutics (AUTL) Accumulated Depreciation & Amortization (2017 - 2025)

Historic Accumulated Depreciation & Amortization for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $6.2 million.

  • Autolus Therapeutics' Accumulated Depreciation & Amortization rose 913.28% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 913.28%. This contributed to the annual value of $7.6 million for FY2024, which is 1506.47% up from last year.
  • Autolus Therapeutics' Accumulated Depreciation & Amortization amounted to $6.2 million in Q3 2025, which was up 913.28% from $4.1 million recorded in Q2 2025.
  • Autolus Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $8.5 million during Q4 2021, with a 5-year trough of $1.8 million in Q1 2024.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $5.2 million (2023), whereas its average is $4.9 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 4948.75% in 2021, then plummeted by 1702.75% in 2023.
  • Over the past 5 years, Autolus Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $8.5 million in 2021, then decreased by 12.25% to $7.4 million in 2022, then fell by 11.55% to $6.6 million in 2023, then grew by 15.06% to $7.6 million in 2024, then fell by 18.53% to $6.2 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $6.2 million for Q3 2025, versus $4.1 million for Q2 2025 and $2.0 million for Q1 2025.